Recombinant IL-9 antibodies

• US 7,354,584 B2
• Filed: 04/12/2004
• Issued: 04/08/2008
• Est. Priority Date: 04/11/2003
• Status: Expired due to Fees

• Current Assignee: Medimmune LLC (Astrazeneca PLC)
• Original Assignee: Medimmune Incorporated (Astrazeneca PLC)
• Inventors: Wu, Herren, Tang, Ying, Watkins, Jeffry D., Davies, Julian, Reed, Jennifer Lynne
• Primary Examiner(s): Gambel; Phillip
• Assistant Examiner(s): SKELDING, ZACHARY S
• Application Number:
  US10/823,253
• Publication Number:
  US 20050002934A1
• Time in Patent Office: 1,457 Days
• Field of Search: None
• US Class Current: 424/145.1
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61K 39/3955 against proteinaceous materials, e.g. enzymes, hormones, lymphokines
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61P 11/00 Drugs for disorders of the respiratory system
• CPC Class Codes: A61P 11/06 Antiasthmatics
• CPC Class Codes: A61P 19/02 for joint disorders, e.g. arthritis, arthrosis
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 31/00 Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• CPC Class Codes: A61P 31/04 Antibacterial agents
• CPC Class Codes: A61P 31/10 Antimycotics
• CPC Class Codes: A61P 31/12 Antivirals
• CPC Class Codes: A61P 31/16 for influenza or rhinoviruses
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 37/00 Drugs for immunological or allergic disorders
• CPC Class Codes: A61P 37/02 Immunomodulators
• CPC Class Codes: A61P 37/06 Immunosuppressants, e.g. drugs for graft rejection
• CPC Class Codes: A61P 37/08 Antiallergic agents antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C07K 16/244 : Interleukins [IL]
• CPC Class Codes: C07K 2317/24 : containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
• CPC Class Codes: C07K 2317/76 : Antagonist effect on antigen, e.g. neutralization or inhibition of binding
• CPC Class Codes: C07K 2317/92 : Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
• CPC Class Codes: G01N 33/6869 : Interleukin

Abstract

The present invention provides novel antibodies that immunospecifically bind to an IL-9 polypeptide and compositions comprising said antibodies. The present invention also provides methods and compositions preventing, treating, managing, and/or ameliorating diseases and disorders associated with aberrant expression and/or activity of IL 9 or IL-9 receptor or subunits thereof, autoimmune diseases, inflammatory diseases, proliferative diseases, and infections comprising administration of one or more antibodies thereof that immunospecifically bind to an IL-9 polypeptide. The invention also encompasses methods and compositions for diagnosing, monitoring, and prognosing these disorders. The present invention further relates to articles of manufacture and kits comprising antibodies that immunospecifically bind to an IL-9 polypeptide.

Claims

1. An isolated antibody comprising a VH CDR1 comprising the amino acid sequence of SEQ ID NO:

26, a VH CDR2 comprising the amino acid sequence of SEQ ID NO;

2, a VH CDR3 comprising the amino acid sequence of SEQ ID NO;

3, a VL CDR1 comprising the amino acid sequence of SEQ ID NO;

62, a VL CDR2 comprising the amino acid sequence of SEQ ID NO;

65, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO;

20.

3. An antibody conjugate comprising:

the antibody of claim 1 or 2 conjugated to a detectable substance.

4. A pharmaceutical composition comprising the antibody of claim 1 or 2 and a pharmaceutically acceptable carrier or excipient.

5. The pharmaceutical composition of claim 4 formulated for pulmonary, intranasal, oral, subcutaneous, intradermal or parental administration.

6. The pharmaceutical composition of claim 4 formulated for sustained release formulation.

7. A lyophilized formulation comprising the antibody of claim 1 or 2.

8. A liquid formulation comprising the antibody of claim 1 or 2.

9. A kit comprising the antibody of claim 1 or 2 in one or more containers, and instructions for use.

2. An isolated antibody which is encoded by the vector deposited as ATCC deposit No. PTA-5913.